Anastrozole
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Anastrozole: No TxGNN Predictions Available — Evaluation Incomplete
One-Sentence Summary
Anastrozole (DrugBank ID: DB01217) is a well-known aromatase inhibitor established in breast cancer therapy. The current Evidence Pack contains no TxGNN predicted indications, and two high-severity data gaps — missing mechanism of action (DG002) and missing safety/label data (DG001, Blocking) — prevent this evaluation from proceeding. A data remediation step is required before a repurposing analysis can be completed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in Evidence Pack |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — No supporting predictions or studies |
| Taiwan Market Status | Not marketed（未上市） |
| Number of Taiwan Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction is available in this Evidence Pack. A mechanistic rationale for repurposing cannot be presented at this stage.
Currently, detailed mechanism of action data is not available (Data Gap DG002). Based on established pharmacology, Anastrozole is a selective aromatase (CYP19A1) inhibitor that suppresses peripheral estrogen biosynthesis, and its efficacy in hormone receptor-positive breast cancer has been demonstrated in multiple large Phase 3 trials. However, until the TxGNN pipeline generates predicted indications for this drug, mechanistic applicability to any new indication cannot be evaluated.
Clinical Trial Evidence
Currently no related clinical trials registered — no TxGNN predicted indication is available to define the search scope.
Literature Evidence
Currently no related literature available — no TxGNN predicted indication is available to define the search scope.
Taiwan Market Information
Anastrozole has no registered licenses in the Taiwan TFDA database as of the query date (2026-03-24).
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No records found in TFDA database |
Note: Anastrozole is commercially available as Arimidex® (AstraZeneca) in multiple markets. If the TFDA query used the INN “ANASTROZOLE” and returned 0 results, it is advisable to re-query using the brand name or common transliterations before concluding the drug is absent from the Taiwan market.
Cytotoxicity
Anastrozole is an antineoplastic agent (breast cancer treatment); this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted / Hormonal therapy — Aromatase inhibitor; not a conventional cytotoxic agent |
| Myelosuppression Risk | Low — aromatase inhibitors do not typically cause clinically significant bone marrow suppression |
| Emetogenicity Classification | Low |
| Monitoring Items | Bone mineral density (osteoporosis and fracture risk), lipid profile, liver function tests, musculoskeletal symptoms (arthralgia, myalgia) |
| Handling Protection | Standard precautions apply; cytotoxic handling protocols not required |
Safety Considerations
Please refer to the package insert for safety information.
TFDA package insert data has not been retrieved (DG001, severity: Blocking). Key warnings, contraindications, and drug-drug interaction data are all unavailable in this Evidence Pack. Full safety profiling is required before any repurposing evaluation can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack is critically incomplete — the TxGNN pipeline returned no predicted indications for Anastrozole, and two data gaps (DG001 Blocking, DG002 High) prevent safety and mechanism analysis. There is no prediction to evaluate.
To proceed, the following is needed:
- Re-run TxGNN prediction pipeline for Anastrozole (DB01217) to generate candidate indications — this is the prerequisite for the entire report
- Retrieve MOA data from DrugBank API (resolves DG002; needed for mechanism-of-action section)
- Download and parse the TFDA package insert for key warnings and contraindications (resolves DG001, Blocking; required for safety evaluation)
- Re-verify Taiwan market status — TFDA query returned 0 results; confirm whether the drug is marketed under the brand name Arimidex® or a generic before concluding it is not marketed in Taiwan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.